Background: The identification of reliable prognostic biomarkers is crucial for optimizing cancer treatment strategies, especially in the era of personalized medicine. This systematic review and meta-analysis evaluate the prognostic significance of the neutrophil-to-eosinophil ratio (NER) in various cancer types, with a focus on its association with overall survival (OS) and progression-free survival (PFS). Methods: We conducted a systematic literature search across PubMed, Scopus, and Web of Science databases for studies published up to 28 July 2024. We performed the meta-analyses with the generic inverse variance method with a random effects model and reported hazard ratios (HR) with 95% confidence intervals (CI). Results: The comprehensive literature search identified 10 studies comprising 2351 patients. Pooled analyses demonstrated that elevated pretreatment NER levels were significantly correlated with poorer OS (HR: 1.74, 95% CI: 1.28–2.36,p< 0.001) and PFS (HR: 1.53, 95% CI: 1.21–1.95,p< 0.001). Subgroup analyses confirmed a consistent adverse association between high NER and OS across various tumor types and geographic locations, although results from studies conducted in the Far East did not reach statistical significance. Conclusions: This meta-analysis demonstrates that elevated NER is associated with poorer OS and PFS in cancer patients, suggesting its potential utility as a non-invasive prognostic marker. Further validation in large, prospective studies is warranted to establish NER’s role in guiding personalized treatment strategies across diverse oncologic contexts.
背景：在精准医疗时代，识别可靠的预后生物标志物对优化癌症治疗策略至关重要。本系统综述与荟萃分析评估了中性粒细胞-嗜酸性粒细胞比值（NER）在多种癌症类型中的预后价值，重点关注其与总生存期（OS）和无进展生存期（PFS）的关联性。方法：我们系统检索了截至2024年7月28日发表于PubMed、Scopus和Web of Science数据库的相关研究。采用随机效应模型的通用逆方差法进行荟萃分析，以风险比（HR）及95%置信区间（CI）呈现结果。结果：经系统检索共纳入10项研究，涉及2351例患者。合并分析显示，治疗前NER水平升高与较差的OS（HR: 1.74, 95% CI: 1.28–2.36, p<0.001）和PFS（HR: 1.53, 95% CI: 1.21–1.95, p<0.001）显著相关。亚组分析证实，在不同肿瘤类型和地域中，高NER与不良OS存在一致关联，但远东地区的研究结果未达到统计学显著性。结论：本荟萃分析表明NER升高与癌症患者较差的OS和PFS相关，提示其作为无创预后标志物的潜在价值。未来需要通过大规模前瞻性研究进一步验证，以确立NER在不同肿瘤临床场景中指导个体化治疗策略的作用。
肿瘤(癌症)患者之家